Search

Amphastar Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

23.58 -0.25

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

23.47

Max

23.8

Belangrijke statistieken

By Trading Economics

Inkomsten

24M

30M

Verkoop

13M

184M

K/W

Sectorgemiddelde

14.148

56.432

EPS

0.8

Winstmarge

16.502

Werknemers

1,976

EBITDA

12M

45M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-6.15% downside

Dividenden

By Acuity

Volgende Winsten

5 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

171M

1B

Vorige openingsprijs

23.83

Vorige sluitingsprijs

23.58

Nieuwssentiment

By Acuity

40%

60%

120 / 339 Rangschikking in Healthcare

Amphastar Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 sep 2026, 23:31 UTC

Amphastar Pharmaceuticals, Inc. is trading lower in after-market hours, continuing a trend of losses with the last three sessions closing lower.

16 sep 2026, 19:43 UTC

Amphastar Pharmaceuticals, Inc. is advancing, having peaked earlier in the session, and remains above its 20-day moving average near the upper end of its one-month range.

10 sep 2026, 20:01 UTC

Amphastar Pharmaceuticals shares are higher Thursday, despite earlier session pullbacks. No specific news was identified to explain the price movement.

8 sep 2026, 20:01 UTC

News

Amphastar Pharmaceuticals is lower today amid a decline in the Pharmaceuticals sub-sector. Analysts recommend "Reduce," with Bank of America reiterating an “underperform” rating.

4 sep 2026, 20:07 UTC

Amphastar Pharmaceuticals is lower today amid broader market declines following a strong jobs report, which has increased selling pressure across risk assets.

3 sep 2026, 19:56 UTC

Amphastar Pharmaceuticals is trading roughly flat amid broader market fluctuations. Treasury yields declined following initial jobless claims data that exceeded expectations.

2 sep 2026, 20:08 UTC

Amphastar Pharmaceuticals is advancing during Wednesday's session, despite earlier pulling back from a session high. No specific news was identified to explain the movement.

26 aug 2026, 20:08 UTC

Amphastar Pharmaceuticals is trading higher today, reflecting a broader market trend amid mixed performance following recent inflation data. The stock remains near its one-month range.

25 aug 2026, 20:07 UTC

Amphastar Pharmaceuticals is higher during Tuesday's session, reflecting a recovery after three consecutive lower finishes amid easing Treasury yields and falling oil prices.

24 aug 2026, 21:01 UTC

Amphastar Pharmaceuticals shares are lower in after-market hours, continuing a five-session decline. No specific news was identified to explain the price movement.

21 aug 2026, 19:56 UTC

Amphastar Pharmaceuticals Inc shares are lower today, despite earlier fluctuations. No specific news has been identified to explain the price movement.

20 aug 2026, 19:51 UTC

Amphastar Pharmaceuticals shares are higher, supported by a positive market environment and economic indicators showing strength in the broader economy.

19 aug 2026, 19:36 UTC

News

Barclays raised its price target on Amphastar Pharmaceuticals to $23.00, contributing to positive sentiment as shares remain well above their 20-day moving average.

18 aug 2026, 19:16 UTC

Amphastar Pharmaceuticals Inc shares are higher today, reflecting market volatility amid rising U.S. Treasury yields and inflation concerns linked to geopolitical tensions.

17 aug 2026, 19:16 UTC

Amphastar Pharmaceuticals Inc. shares are lower amid routine market fluctuations and concerns over slowing growth following declines in U.S. retail sales and consumer sentiment.

14 aug 2026, 20:01 UTC

Amphastar Pharmaceuticals is trading higher, rebounding from an early session low. The stock remains above its 20-day moving average despite no specific news.

12 aug 2026, 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower in Wednesday's session, continuing a decline from Tuesday's close amid fluctuating U.S. Treasury yields and inflation data.

11 aug 2026, 19:56 UTC

News

Amphastar Pharmaceuticals reported Q2 revenue of $183.9 million, exceeding expectations. Shares are modestly higher amid strong demand for key products and new launches.

10 aug 2026, 19:36 UTC

News

Amphastar Pharmaceuticals reported Q2 earnings of $0.70 per share on $183.9 million in revenue, but shares are trading lower today amid a slight net income decline.

7 aug 2026, 19:51 UTC

News

Amphastar Pharmaceuticals reported Q2 EPS of $0.91, exceeding estimates. Revenue also surpassed expectations, contributing to a positive market response and higher shares.

6 aug 2026, 23:02 UTC

News

Amphastar Pharmaceuticals reported second-quarter sales of $183.9 million, exceeding expectations. Shares are trading higher in after-market hours following the strong results.

4 aug 2026, 19:51 UTC

Amphastar Pharmaceuticals is trading lower today, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

3 aug 2026, 19:46 UTC

Amphastar Pharmaceuticals Inc is trading higher, reaching a session high amid positive market conditions and falling oil prices influencing investor sentiment.

31 jul 2026, 19:36 UTC

Amphastar Pharmaceuticals is declining today, continuing a downward trend since Thursday. The stock reached a session low earlier this morning amid broader market volatility.

30 jul 2026, 19:28 UTC

Amphastar Pharmaceuticals Inc. shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector, reflecting broader sector weakness during Thursday's session.

29 jul 2026, 20:41 UTC

Amphastar Pharmaceuticals shares are lower in after-market trading, continuing a decline amid rising crude oil prices and geopolitical tensions in the Middle East.

28 jul 2026, 20:02 UTC

Amphastar Pharmaceuticals shares are higher today, diverging from a broader market decline amid a sell-off in technology stocks across Asian markets.

24 jul 2026, 19:06 UTC

Amphastar Pharmaceuticals is trading higher, supported by a pullback in crude oil prices, which has eased some inflationary pressures affecting investor sentiment.

22 jul 2026, 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower today, continuing a four-session decline amid market uncertainty ahead of the Federal Reserve meeting on July 29.

21 jul 2026, 19:46 UTC

Amphastar Pharmaceuticals Inc is trading lower, continuing a three-session decline. No specific news was identified to explain the stock's performance.

Peer Vergelijking

Prijswijziging

Amphastar Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

-6.15% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 22.167 USD  -6.15%

Hoogste 30 USD

Laagste 20 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Amphastar Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

6 ratings

0

Buy

5

Hold

1

Sell

Sentiment

By Acuity

120 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.